| answer text |
<p>We have made no assessment. The National Institute for Health and Care Excellence
(NICE) assesses medicines on the basis of their value to patients and to the National
Health Service. The source of financial support in developing each medicine is not
assessed.</p><p> </p><p>The NHS is required by law to ensure that all medicines recommended
by NICE are funded within three months, ensuring patient access to cost-effective
medicines in England. New medicines are not subject to payments under the voluntary
Pharmaceutical Price Regulation Scheme, and NHS England monitors access to innovative
medicines via the Innovation Scorecard in recognition of the value this Government
places on innovation.</p><p> </p><p>Many countries fund research and development (R&D),
often at an early stage. Private companies also invest in R&D. It is not possible
to assess the contribution made by public investment or private investment in bringing
products to market.</p><p> </p><p>The Government and its partners recently published
the response to the Accelerated Access Review which sets out plans to give patients
quicker access to life-changing treatments and make the United Kingdom the best place
in the world for industry to invest and innovate. A total of £86 million of funding
has already been committed to make the vision a reality.</p><p> </p><p> </p>
|
|
